News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
Protagonist Therapeutics announced positive final data from rusfertide Phase 2 REVIVE study for treating polycythemia vera, presented at ASH 2024 -
-
-
COMMUNIQUÉ DE PRESSE
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
Protagonist Therapeutics to participate in fireside chat at 7th Annual Evercore ISI HealthCONx Conference on Dec 3-5, 2024. Company's CEO, Dinesh V. Patel, to discuss latest developments -